Loading company
Lisata Therapeutics, Inc.
LSTA · Nasdaq · ·
Next earnings: November 5, 2026
$1.46-3.6%Sep 29 close
- 1M
- -13.9%
- 6M
- -71.0%
- 1Y
- -44.5%
- 5Y
- -92.0%
LSTA · Nasdaq · ·
Next earnings: November 5, 2026
$1.46-3.6%Sep 29 close
Lisata Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $70K | -100.00% |
| Profit | -$2.9M | -$4.7M | +37.13% |
| Profit per share | -$0.32 | -$0.54 | +40.74% |
| Free Cash Flow | -$2.6M | -$4M | +33.04% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform ® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the first quarter of 2027, encompassing anticipated data milestones from its ongoing clinical trials. For a comprehensive overview of certepetide's mechanism of action, please view our informative short film.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Lisata Therapeutics, Inc.’s Item 2.02 8-K filed November 6, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Lisata Therapeutics, Inc. has no earnings call transcript available.